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Abstract
Background Approximately 15–20% of ulcerative colitis patients and 20–40% of those with Crohn’s disease experience 
extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage 
EIMs affecting multiple organs that variably correlate with intestinal disease activity. Vedolizumab is a monoclonal antibody 
for the treatment of IBD with a gut-selective mechanism of action.
Aims This report evaluates whether vedolizumab is an effective treatment of EIMs, given its gut-specific mechanism of 
action.
Methods We report 8 case studies of patients with various EIMs, including pyoderma gangrenosum, peripheral arthralgia/
arthritis, axial arthropathies, erythema nodosum, and uveitis, who received vedolizumab therapy.
Results Vedolizumab therapy was effective for pyoderma gangrenosum in ulcerative colitis, uveitis, erythema nodosum, 
polyarticular arthropathy, and ankylosing spondylitis/sacroiliitis but did not provide sustained benefit for the treatment of 
pyoderma gangrenosum in a patient with Crohn’s disease.
Conclusions These cases demonstrate the potential of vedolizumab as a treatment of EIMs in patients with IBD.
Keywords Inflammatory bowel disease · Crohn’s disease · Ulcerative colitis · Extraintestinal manifestations
Introduction
Inflammatory bowel disease (IBD), which comprises ulcera-
tive colitis (UC) and Crohn’s disease (CD), is characterized 
by chronic intestinal inflammation that results in mucosal 
ulceration and tissue damage [1]. Although the etiology of 
IBD is not yet fully elucidated, multiple factors including 
genetic susceptibility, environmental influences, the intesti-
nal microbiota, and defective host defense mechanisms con-
tribute to the pathological process [2]. Failure to adequately 
control inflammation frequently leads to bowel damage and 
disability [3], and many patients will eventually require sur-
gery [4].
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Early introduction of highly effective anti-inflamma-
tory therapy has been shown to prevent IBD-related com-
plications in both UC and CD [5]. In CD, treatment with 
tumor necrosis factor (TNF) antagonists has demonstrated 
increased rates of mucosal healing and clinical remission 
[6–8] and decreased rates of hospitalization and surgery [3]. 
Similar results have been obtained with infliximab therapy 
in UC. These findings have led to a fundamental change in 
the treatment paradigm for both diseases such that the recent 
STRIDE (Selecting Therapeutic Targets in Inflammatory 
Bowel Disease) guidelines have incorporated endoscopy, 
an objective marker of inflammation, as a treatment target 
in both conditions [9].
Extraintestinal Manifestations
Despite this nascent emphasis on controlling inflammation, 
little attention has been paid to the treatment of extraintes-
tinal manifestations (EIMs) in IBD. Prevalence estimates 
currently suggest that EIMs are present in 15–20% of UC 
patients and 20–40% of CD patients [10]. EIMs adversely 
affect quality of life, and some EIMs, such as primary scle-
rosing cholangitis or venous thromboembolism, can be life-
threatening [11].
Currently, the pathophysiology of EIMs is poorly under-
stood; however, possible mechanisms include antigen leak-
age from the gut resulting in immune complex-mediated 
small vessel vasculitis and molecular mimicry, whereby 
shared epitopes between intestinal bacteria and antigens of 
the joints and skin trigger immune responses at extraintesti-
nal sites [12]. Although the relationship between EIMs and 
intestinal disease activity varies depending on the type of 
EIM, in general, effective treatment of the local intestinal 
inflammation should control many EIMs of IBD.
The musculoskeletal, dermatologic, ocular, hepatopan-
creatobiliary, renal, and hematologic systems are common 
organ systems affected (Table 1); and of those, musculo-
skeletal EIMs are the most common [13]. Peripheral arthral-
gia/arthritis, which occurs with an estimated prevalence of 
5–20% [14], can be classified as type 1 (pauciarticular) or 
type 2 (polyarticular). Type 1 disease mainly affects large 
joints, including the knees, ankles, wrists, and elbows, and 
usually correlates with IBD activity [14]. Type 2 mainly 
affects small joints with a symmetrical distribution, includ-
ing the metacarpophalangeal and interphalangeal joints, and 
generally does not correlate with luminal inflammation [14].
Axial arthropathies, a second type of musculoskeletal 
EIM, have a prevalence between 5 and 12% (Table 1) [15]. 
Axial arthropathies include ankylosing spondylitis, a sys-
temic inflammatory disease that affects the sacroiliac joints, 
the spine, and potentially other joints, but may also present 
as isolated sacroiliitis. Both versions usually do not cor-
relate with intestinal IBD activity [16]. TNF antagonists 
are highly effective treatment for ankylosing spondylitis 
[17]. Although the European Crohn’s and Colitis Organi-
zation (ECCO) currently recommends that TNF antagonist 
therapy be used early in IBD patients with axial arthritis 
Table 1  Common extraintestinal manifestations
Site Prevalence Manifestation Correlates with 
bowel inflamma-
tion?
Musculoskeletal 5–20% [14] Peripheral arthralgia/arthritis Type 1 (large joints) Yes [14]
Type 2 (small joints) No [14]
5–12% [15] Axial arthropathies Ankylosing spondylitis No [16]
Isolated sacroiliitis No [16]
Dermatologic 2–34% [13] Erythema nodosum Yes [25]
Pyoderma gangrenosum No [25]
13% [20] Hidradenitis suppurativa Yes [20]
Ocular 0.3–5% [13] Episcleritis Yes [25]
Uveitis Case dependent [28]
Hepatopancreatobiliary 30% [11] Abnormal liver chemistry Case dependent [11]
13–34% [13] Gallstones No [11]





Metabolic 20–50% [11] Low bone mass/osteoporosis Case dependent [11]
Renal 6–23% [13] Kidney stones Case dependent [13]
Hematologic 1.4–3.3% [11] Thromboembolism Yes [11]
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and for other musculoskeletal EIMs that are refractory to 
nonsteroidal anti-inflammatory drugs [11], only a few stud-
ies have investigated the use of these agents in IBD-related 
arthritides. A sub-analysis of the CHARM trial, including 
420 CD patients with arthritis and arthralgia symptoms at 
baseline, showed that 70 of the 281 patients (24.9%) treated 
with adalimumab were free of arthritis and arthralgia after 
56 weeks of therapy compared with 11 of the 139 patients 
(7.9%) treated with placebo [18].
Dermatologic EIMs include a broad spectrum of skin dis-
eases, and it is not uncommon for patients to develop multi-
ple manifestations concurrently during the natural course of 
IBD. Two major immune-mediated forms of dermatologic 
EIMs are erythema nodosum (EN) and pyoderma gangreno-
sum (PG) [19]. In addition, hidradenitis suppurativa affects 
about 13% of IBD patients and is characterized by pain-
ful, inflamed skin follicles commonly found in the axillae, 
inguinal, and anogenital areas [20]. Psoriasis is another skin 
disease that is common among IBD patients. The prevalence 
of psoriasis in the general population is approximately 1.5% 
[21], and patients with IBD have a sixfold risk of developing 
the disease [22]. As is the case for spondyloarthropathies, 
TNF antagonists are highly effective therapy for psoriasis. 
However, some patients develop psoriasiform lesions, typi-
cally on the scalp, hands, and feet following prolonged treat-
ment with these drugs. In many cases, treatment requires 
withdrawal of the TNF antagonist and switching to another 
class of agent, typically ustekinumab or vedolizumab.
EN, which affects 15% of CD and 10% of UC patients 
[23], is a small vessel vasculitis that results in panniculitis. 
The lesions typically present as inflamed nodules of 1 cm 
to 5 cm in diameter on the lower limbs and occasionally on 
the arms and trunk [23]. Treatment of EN usually consists of 
corticosteroids and intensification of medical therapy to con-
trol intestinal disease. A strong correlation exists between 
the presence of EN and intestinal disease activity.
PG is less common, occurring in 0.4–2% of IBD 
patients, and is usually more severe than EN [24]. Patho-
logically, PG is characterized by full thickness necrosis of 
the skin due to vasculitis. The disease manifests as nodules 
that evolve into deep ulcerations typically on the shins but 
can develop anywhere on the skin [23]. PG is more com-
mon in UC than CD. Unlike EN, PG is normally independ-
ent of luminal IBD disease activity [25]. Although ECCO 
guidelines suggest corticosteroids as a first-line therapy for 
PG, severe cases require treatment with immunosuppres-
sives such as azathioprine, TNF antagonists, or calcineurin 
inhibitors [11]. A small (n = 13) randomized controlled 
trial for the treatment of PG showed 6 (46%) of the inflixi-
mab treated patients improved compared with only 1 of 17 
(6%) patients assigned to placebo [26].
Ocular complications include episcleritis and uveitis 
and are often present concurrently with other EIMs [27]. 
Episcleritis, which is more common in CD than in UC, 
often correlates with intestinal disease activity [25] and 
presents with hyperemia, irritation, burning, and tender-
ness [28]. Uveitis is less common than episcleritis, and 
the association with IBD activity is variable. Patients with 
uveitis present with ocular pain, blurred vision, photo-
phobia, and headaches [28]. While some cases of epis-
cleritis are self-limiting, the risk of blindness associated 
with uveitis mandates ophthalmologic referral and prompt 
initiation of therapy [28]. ECCO guidelines currently rec-
ommend topical corticosteroids for symptomatic treat-
ment and systemic corticosteroids or immunosuppressives, 
including biologics, in severe or resistant cases [11, 29].
Vedolizumab for the Treatment of EIMs
Vedolizumab is unique among biologics used to treat IBD 
because it specifically targets the gastrointestinal tract [30]. 
Vedolizumab binds to the α4β7 integrin that is expressed on 
activated gut-homing T lymphocytes, and blocks the interac-
tion of α4β7 and mucosal addressin cell adhesion molecule 1 
(MAdCAM-1) [31]. MAdCAM-1 is preferentially expressed 
on the endothelium of blood vessels in the gastrointestinal 
tract. The gastrointestinal tract-specific interaction between 
α4β7 integrins and MAdCAM-1 allows for gut-targeted 
therapy, thereby likely reducing side effects associated with 
systemic immunosuppression.
The gut-selective mode of action of vedolizumab has 
demonstrated efficacy in the treatment of UC and CD in 
the phase 3 GEMINI 1 [32] and GEMINI 2 [33] studies, 
respectively. An integrated summary of 6 phase 2 and phase 
3 vedolizumab trials also provided evidence for the safety of 
vedolizumab, which included a low incidence of the infec-
tious side effects that are typically associated with non-selec-
tive treatments [34].
Although the GEMINI studies were not powered to 
assess EIMs, post hoc analyses of the GEMINI 2 CD data 
indicated a potential benefit with vedolizumab in resolv-
ing symptoms of arthralgias. In these analyses, EIMs 
were evaluated post hoc and defined by the CD Activity 
Index (CDAI) complications component as the presence 
of arthritis/arthralgia, iritis/uveitis, EN, PG, aphthous 
stomatitis, or fever. Resolution of EIMs was defined by 
the absence of CDAI complications at each post-baseline 
study visit during the 52-week study [35]. Kaplan–Meier 
estimates for the resolution of these events were 18% 
at week 26 and 43% at week 52 in vedolizumab-treated 
patients (compared with 4 and 23% in those assigned to 
placebo, respectively) with a hazard ratio of 1.84 (95% 
confidence interval, 0.91–3.71) [35]. Analysis of these 
data also revealed that patients who received vedolizumab 
were 32% more likely to achieve sustained resolution of 
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arthritis/arthralgia and 21% less likely to have a worsening 
or new occurrence than those assigned to placebo [36]; 
however, few descriptions regarding the efficacy of ved-
olizumab on EIMs based on real-world clinical experience 
have been published.
Herein, we present 8 cases describing our clinical 
experience with vedolizumab for the treatment of IBD 
patients who present with various EIMs including periph-




A 50-year-old male with CD diagnosed in 1992 developed 
ankylosing spondylitis and sacroiliitis in 2002. The sacro-
iliitis presented with edema in the lowest sacral segment 
and the highest coccyx segment (Fig. 1). Prior treatment 
consisted of infliximab from 2002 to 2014, prednisolone 
for 2 months between 2012 and 2013, and azathioprine 
from 2007 to 2014. Infliximab and azathioprine were 
discontinued in 2014 because of recurrent peritonsillar 
abscesses, infectious keratoconjunctivitis, acne caus-
ing skin abscesses, and failure to achieve symptomatic 
remission. The patient then initiated treatment with ved-
olizumab. At the time, the patient had 3–4 bowel move-
ments per day with some mucus, a fecal calprotectin con-
centration of 722 mg/kg, and primary symptoms of back 
pain, stiffness, and joint pain. Five months after initiation 
of treatment with vedolizumab, these symptoms resolved, 
and the patient had 1 bowel movement per day without 
mucus and a fecal calprotectin concentration that had 
decreased to 33 mg/kg. Overall, CD symptoms improved 
and were well controlled throughout vedolizumab treat-
ment. One year after resolution of symptoms, the patient 
experienced acne-like skin lesions on the face, which were 
diagnosed as rosacea that immediately resolved with tet-
racycline treatment.
Case 2
A 44-year-old male with CD initially diagnosed in 2009 
developed polyarthritis in 2010. He had also been expe-
riencing back pain since 1991. Prior treatments included 
prednisolone for 2 months in 2009 and 1 month in 2010, 
budesonide for 1 month in 2009 and 2 months in 2015, 
methotrexate for 2 months in 2010 (discontinued because of 
diffuse skin rash), azathioprine for 1 week in 2009 (discon-
tinued because of pancreatitis), adalimumab for 1 month in 
Table 2  Cases
CD Crohn’s disease, EIM extraintestinal manifestation, EN erythema nodosum, IBD inflammatory bowel disease, PG pyoderma gangrenosum, 
UC ulcerative colitis
Age IBD EIM Correlates with IBD? Concomitant 
medications
Outcome of vedolizumab treatment
Case 1 50 CD Ankylosing spondylitis and sacroiliitis No None Resolved 5 months into vedolizumab treat-
ment
Case 2 44 CD Polyarthritis (back and knees) Yes Budesonide Resolved 4 months into vedolizumab treat-
ment
2 years into vedolizumab treatment, knee 
pain remains resolved, back pain has 
returned
Case 3 34 UC Joint and back pain Yes None Resolved 1 month into vedolizumab treat-
ment
Case 4 18 UC Polyarticular arthropathy No Mesalamine Resolved after third dose of vedolizumab
Case 5 46 CD EN Yes Mesalamine Resolved after third dose of vedolizumab
Case 6 24 UC PG No None Resolved after sixth dose of vedolizumab
Case 7 87 CD PG No Methotrexate PG improved but not resolved after 6 months
PG resolved after 4 months of increasing 
infusion frequency to every 4 weeks
Recurrent PG 9 months after increasing infu-
sion frequency
PG at pre-vedolizumab severity 12 months 
after increasing infusion frequency
Vedolizumab discontinued, PG resolved after 
treatment with ustekinumab
Case 8 24 UC Uveitis Case dependent Mesalamine Resolved after third dose of vedolizumab
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2010 (discontinued because of swollen and painful joints), 
sulfasalazine for 1 month in 2011 (discontinued because 
of lack of response), and natalizumab from 2011 to 2014.
Natalizumab was effective in controlling both the luminal 
symptoms and the polyarthritis; however, it was discontin-
ued for safety concerns because the patient was positive 
for antibodies to the John Cunningham (JC) virus. After 
discontinuation, the patient presented with back pain likely 
caused by degenerative changes and knee pain from arthri-
tis. Intestinal symptoms included 4–5 bowel movements per 
day with a small amount of blood and mucus and moder-
ate abdominal pain. Vedolizumab treatment was initiated in 
2014, and 4 months later all of his arthritic complaints had 
resolved. Although some back pain returned 2 years after 
initiation of treatment, the patient’s knee pain remained 
resolved. Furthermore, the patient’s stool frequency had 
improved to 2 loose stools per day with no blood or abdomi-
nal pain. It is noteworthy that this patient developed a peri-
anal abscess that was drained in 2015 and a perianal fistula 
that was resected in 2016. It is unclear whether a causal 
relationship exists between vedolizumab and these events.
Case 3
A 34-year-old male with UC diagnosed in 2012 presented 
with joint and back pain in 2013. The pain mainly affected 
his back; however, he also had peripheral arthritis type 1 
with severe pain in his hips, knees, and muscles. No diag-
nosis of sacroiliitis was confirmed despite MR imaging of 
the lumbosacral spine and pelvis. Prior treatments included 
prednisolone for 2 months in 2013, mesalamine for 1 week 
in 2013 (discontinued because of myocarditis), infliximab 
for 14 months between 2013 and 2014 (discontinued because 
of lack of efficacy and development of antidrug antibodies), 
and golimumab for 7 months between 2014 and 2015 (dis-
continued because of insomnia and migraine).
Vedolizumab treatment was initiated in 2015, and after 
1 month the patient’s back and joint pain resolved. However, 
for the first 5 months he received vedolizumab, the patient 
experienced arthralgias in both his back and peripheral joints 
approximately 5 days before the vedolizumab infusions. One 
year after resolution of symptoms, the patient developed pit-
yriasis rosea on his abdomen, which resolved spontaneously 
within 2 months without treatment. The patient continues to 
be in remission on vedolizumab therapy.
Case 4
An 18-year-old female with UC diagnosed in 2014 had pol-
yarticular arthropathy diagnosed in 2016. At the time of 
presentation, the patient was being treated with mesalamine 
and was naïve to corticosteroids.
Although a definitive diagnosis of UC was not made until 
2016, the patient had been experiencing arthralgias in her 
hands and knees since her initial presentation. Colonos-
copy showed no active disease, and her C-reactive protein 
(CRP) and fecal calprotectin concentrations were normal; 
however, random colon biopsies revealed mildly active 
Fig. 1  MRI findings of the 50-year-old male in case 1 before treatment. Arrows in the axial MR image of the sacroiliac joints indicate articular 
irregularities and periarticular edema as signs of sacroiliitis
830 Digestive Diseases and Sciences (2018) 63:825–833
1 3
histopathologic disease. Although the entire colon appeared 
to be normal on endoscopic examination, histological evalu-
ation revealed mild-to-moderate active disease. Characteris-
tics of mild-to-moderate chronic disease, including cryptitis, 
crypt abscesses, mild-to-moderate mucosal ulceration, and 
moderate crypt architectural distortion, were observed. The 
patient opted to initiate vedolizumab after being offered the 
options of treatment with corticosteroid, immunosuppres-
sives, or TNF antagonists. The patient noted that the joint 
pains resolved completely after the third induction dose of 
vedolizumab.
Case 5
A 46-year-old female with CD diagnosed in 2005 received 
multiple courses of corticosteroid therapy resulting in initia-
tion of azathioprine. However, this agent was discontinued 
because pancreatitis developed within 2 weeks of treatment. 
Although infliximab monotherapy was started, it was not 
possible to provide continuous treatment for insurance rea-
sons. In 2015, the patient experienced a rash and shortness 
of breath following re-initiation of infliximab and the medi-
cation was discontinued.
In 2016, the patient presented with right lower quadrant 
pain and increasingly frequent non-bloody stools. Physical 
examination revealed right lower quadrant tenderness and a 
questionable mass. Tender, raised red nodules of EN were 
present on the extensor surfaces of both tibias. Her white 
blood cell (WBC) count was 14.6 × 109/L, erythrocyte sed-
minentation rate (ESR) was 34 mm/h, and the serum CRP 
concentration was 6 mg/L. Stool calprotectin concentrations 
were elevated. Magnetic resonance enterography showed 
active inflammation of the terminal ileum. A colonoscopy to 
the terminal ileum revealed a normal colon examination, but 
multiple ulcers were present in the terminal ileum. Biopsies 
from the ileum were consistent with active CD, with a single 
non-caseating granuloma demonstrated.
Treatment with vedolizumab was initiated, and resolution 
of the skin lesions followed the third infusion of the drug. 
The abdominal pain resolved completely after the fifth dose. 
The CRP, ESR, and stool calprotectin values were also nor-
mal after the fifth dose. The patient continued treatment with 
vedolizumab, and mesalamine was discontinued. Repeat 
endoscopy revealed a normal colon and ileum; however, 
the ileocecal valve was noted to be deformed and mildly 
stenotic. Biopsies of the colon and valve were normal, and 
biopsies of the ileum revealed mild enteritis.
Case 6
A 24-year-old male with comorbid osteoporosis and dia-
betes, who was diagnosed with UC in 1998, presented 
with PG in 2016. Prior treatments were 6-mercaptopurine, 
mesalamine, corticosteroids, and multiple TNF antagonists. 
The patient underwent a colectomy and permanent ileos-
tomy in 2012.
In 2016, the patient presented with a peristomal ulcera-
tion. The lesion had irregular borders and was diagnosed by 
a dermatologist as PG. The patient was positive for anti-sac-
charomyces cerevisiae antibodies (ASCA) and anti-neutro-
phil cytoplasmic antibodies (ANCA). The patient deferred 
corticosteroid treatment because of his osteoporosis. Small 
bowel was normal by endoscopy and video capsule endos-
copy. The patient began vedolizumab therapy in 2016, and 
the lesion resolved after the sixth dose. The patient remains 
on vedolizumab and has been lesion free for 1 year.
Case 7
An 87-year-old patient with a history of CD underwent 
an end ileostomy in 1972, and in 2014, he developed peri-
stomal PG. The patient was treatment naïve since surgery, 
CD symptoms were well controlled, and luminal disease was 
not present at the time of PG presentation. Treatment with 
infliximab and methotrexate was commenced in 2015, lead-
ing to improvement in PG. However, 6 months after initia-
tion of treatment, the patient developed a diffuse rash and 
infliximab was discontinued. Subsequently, the peristomal 
ulcer worsened. After a period without any biologic therapy, 
the patient began treatment with vedolizumab and contin-
ued methotrexate. Six months later, the PG had improved 
but was not resolved. Although PG improved with main-
tenance infusions dosed every 8 weeks, it began to worsen 
4–5 weeks after each infusion. In response, treatment was 
intensified to an infusion every 4 weeks, which led to com-
plete healing of PG after 4 months.
Nine months into the adjusted vedolizumab infusion 
schedule, the patient began to experience recurrent PG. 
Three months later, PG worsened to the severity level exhib-
ited before the initiation of vedolizumab. The patient discon-
tinued vedolizumab and began treatment with ustekinumab 
in 2017 and achieved complete healing.
Case 8
A 24-year-old male with UC diagnosed in 2014, following 
presentation with bloody diarrhea that required hospitaliza-
tion, developed uveitis in 2016. After intravenous corticos-
teroid induction therapy, the patient received mesalamine for 
maintenance or remission, which was successful for 2 years. 
In 2016, the patient presented with headaches, bilateral ocular 
pain, and blurred vision without symptoms of bloody diar-
rhea or abdominal cramps. Although the stool fecal calpro-
tectin concentration was within the normal range, the CRP 
concentration was 14 mg/L and ESR was 64 mm/h. An ini-
tial colonoscopy revealed moderately active pancolitis, and 
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biopsies confirmed the endoscopic findings. The patient’s 
ophthalmologic assessment revealed anterior chamber uveitis. 
Treatment with oral prednisone 40 mg daily for 2 weeks was 
initiated with tapering by 5 mg weekly. The patient developed 
recurrent symptoms when the prednisone dose was reduced 
to 15 mg. At this time, a colonoscopy revealed mild disease 
of the rectum and sigmoid, which was confirmed by biopsies.
Subsequently, treatment with vedolizumab was initiated. 
Corticosteroid tapering was resumed after the third dose of 
vedolizumab. The patient had no recurrence of uveitis and 
was off prednisone 1 year later, when a repeat colonoscopy 
showed a normal mucosa. Biopsies confirmed the absence 
of active histopathologic inflammation.
Discussion
The occurrence of EIMs with IBD is an important challenge 
for clinicians who treat IBD. These entities are relatively 
common and contribute substantially to the burden of illness 
of both CD and UC. Very little high-quality research has 
been conducted into the pathogenesis, epidemiology, or ther-
apy of these conditions. Consequently, many important gaps 
exist in our approach to the management of EIMs. Although 
conventional wisdom is that some of the individual EIMs, 
such as arthralgias, track closely with the presence of lumi-
nal disease activity, whereas others, such as sacroiliitis, fol-
low an independent course, this dogma can be challenged.
In keeping with this notion, some of the cases presented 
in this paper describe patients with quiescent gastrointestinal 
tract disease and continuing symptoms of arthralgias. Alter-
natively, cases of uveitis and sacroiliitis are depicted that 
resolve with more intense management of intestinal disease. 
Even though these cases cannot be considered strong scien-
tific evidence to refute the established relationships between 
EIMs and disease activity, the classic studies that have pre-
viously evaluated this question did not rigorously evaluate 
patients’ luminal disease activity by endoscopy, nor did they 
assess EIMs using objective or qualitative measures. These 
cases are valuable in that they underscore the need to further 
examine the relationship between intestinal disease activity 
and EIM severity using rigorous methodologies.
TNF antagonists are thought to be effective for the 
treatment of EIMs, and a systematic review that included 
9 interventional, 7 open-label, and 13 noninterventional 
studies concluded that they are beneficial for the treatment 
of musculoskeletal, cutaneous, and ocular manifestations 
[37]. Data from the CARE study, a large multicenter open-
label phase 3 trial in patients with moderately to severely 
active CD, show that after 20 weeks of adalimumab treat-
ment in 497 patients with baseline EIMs, 79% had resolu-
tion of at least one EIM and 51% were free of EIM signs 
and symptoms [38]. A multinational phase 3 trial has also 
shown that adalimumab is effective in treating idiopathic 
uveitis by reducing both inflammation and visual impair-
ment [13]. For PG, specifically, infliximab demonstrated 
complete healing of skin lesions in a retrospective study 
of 13 patients with IBD and medically refractory PG; 3 
patients had a complete response to only induction inflixi-
mab therapy, while 10 patients required infusions every 
4–12 weeks for maintained PG healing [26, 39].
Although TNF antagonists are beneficial for the manage-
ment of EIMs, these agents are not uniformly effective, are 
poorly tolerated in some patients, and frequently become 
ineffective owing to sensitization or other poorly defined 
mechanisms. Our observations here suggest that vedoli-
zumab may be an effective treatment option for the manage-
ment of EIMs, especially those that track closely with lumi-
nal disease. In this case series, vedolizumab therapy was 
effective for PG in UC, uveitis, EN, polyarticular arthropa-
thy, and ankylosing spondylitis/sacroiliitis, but did not pro-
vide sustained benefit for the treatment of PG in CD. Nota-
bly, most of these patients had good control of their luminal 
IBD, which suggests that control of intestinal inflammation 
may be critical for the management of EIMs. The efficacy 
of vedolizumab in treating EIMs that are known to correlate 
with disease is not surprising, as analysis of the GEMINI 
2 clinical trial data showed that patients treated with ved-
olizumab were 32% more likely to achieve sustained reso-
lution of arthritis/arthralgia compared with placebo [40]. 
However, the cases described herein of patients with EIMs 
that were traditionally thought to be independent of bowel 
disease, such as PG and axial spondyloarthritis (SpA), are 
interesting. These results are consistent with a recent study 
conducted by Orlando and colleagues [41] in 53 patients 
with IBD-associated SpA, the majority of whom had failed 
to respond to a TNF antagonist and were corticosteroid 
dependent. Of the 14 patients with active SpA in this study, 
6 patients demonstrated a strong clinical benefit after ini-
tiation of vedolizumab treatment. In another observational 
study, a correlation was shown between an improvement in 
symptoms and decrease in MR-defined bone marrow edema 
and gut inflammation in patients with active SpA [42].
In summary, the findings of these cases highlight the 
need to further examine the relationship between intestinal 
disease activity and EIMs and suggest that vedolizumab 
has a role in the management of these patients. Given the 
limited data available, large-scale cohort studies and ran-
domized controlled trials that employ objective measures 
of inflammation are needed before these questions can be 
answered definitively.
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